Net sales during the quarter increased by 8.9% YoY to Rs 809.63 crore. Profit before tax (PBT) (before exceptional items) from continuing operations for the fourth quarter was Rs 178 crore, recording a growth of 6% YoY. GSK Pharmas consolidated net profit surged to Rs 1,694.72 crore in FY22 from Rs 358.15 crore in FY21. Net sales rose by 12% to Rs 3,278.03 crore in FY22 over FY21. PBT (before exceptional) from continuing operations for the year at Rs 767 crore, registering a growth of 22% YoY. EBITDA margin improved by 3%. Sridhar Venkatesh, managing director, GlaxoSmithKline Pharmaceuticals, said, ?During the year, our General Medicines portfolio continued to gain market share in their respective categories. Our execution focus on key brands helped us revitalise growth particularly in the anti-infectives, dermatology and pain segments. While our vaccines business was impacted due to low vaccination rates, many of our key brands gained share in a declining market, fuelled by disciplined execution. We continue to maintain market leadership in the private vaccines market. During the quarter, we concluded the transfer of Iodex and Ostocalcium brands to GlaxoSmithKline Asia, as part of GSK plcs plans to create two world class companies in pharmaceuticals and consumer healthcare.? The board recommended a dividend of Rs 90 per share which includes a special dividend of Rs 60 per share. GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the worlds leading research-based pharmaceutical and healthcare companies. The scrip rose 0.93% to currently trade at Rs 1528.20 on the BSE. Powered by Capital Market - Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.